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2 
ABSTRACT 39 
Cell therapy is an attractive strategy for enhancing post-stroke recovery. Different cell types 40 
and several treatment strategies have been successfully applied in animal models, but efficacy 41 
in stroke patients has not yet been confirmed. We hypothesize that the significant design 42 
differences between preclinical and clinical trials may account for this situation. Using a meta-43 
analysis approach and comparing preclinical with clinical trials, we reveal and discuss 44 
preliminary evidence for such design differences. While available datasets are not yet 45 
numerous enough to draw definitive conclusions, these findings may represent signposts on 46 
the route to efficacy by harmonizing preclinical and clinical study designs. 47 
3 
Abbreviations 48 
ART        adhesive removal test 49 
BBB        blood-brain barrier 50 
CI            confidence intervals 51 
FMS        Fugl-Meyer Scale 52 
mBI         modified Barthel Index 53 
MSC        mesenchymal stem/stromal cell 54 
MNC       mononuclear cell 55 
mNSS      modified neurological severity score  56 
mRS        modified Rankin Scale 57 
NIHSS     National Institutes of Health Stroke Scale 58 
NRCT      non-randomized controlled trial 59 
NSC         neural stem cell 60 
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses 61 
RCT         randomized controlled trial 62 
SMD        standardized mean differences 63 
T1DM      type 1 diabetes mellitus 64 
T2DM      type 2 diabetes mellitus 65 
66 
4 
Cell-based therapy has been proposed as a promising paradigm for ischemic stroke for almost 67 
two decades1. Different types of cells, particularly mesenchymal stem/stromal cells (MSCs), 68 
neural stem cells (NSCs) and mononuclear cells (MNCs), have been successfully tested in 69 
animal models. Several mechanisms, such as (limited) cell replacement, immunomodulation, 70 
as well as promotion of angiogenesis and neurogenesis, have been claimed be responsible for 71 
the observed improvements2-4.  72 
    Although a number of early-phase clinical studies investigating cell therapy for ischemic 73 
stroke have been conducted, convincing evidence of efficacy is still lacking5-8. Inadequate 74 
quality of preclinical tests has been previously considered as a major reason for unsuccessful 75 
translation of experimental stroke therapies into the clinic, but the quality of preclinical stroke 76 
studies is clearly improving9. However, significant design differences between preclinical and 77 
clinical trials may hinder translation.  Hence, it is essential to explore how well the currently 78 
described preclinical and clinical trial designs correspond to each other in order to devise 79 
innovative ways for advancing clinical translation of cell therapies in stroke.  80 
An objective way to approach such problems is to conduct a systematic meta-analysis. 81 
Therefore, we have adopted this approach to: 1) estimate the current cell therapy efficacies in 82 
both animal stroke models and stroke patients; 2) explore the sources of heterogeneity in 83 
preclinical and clinical studies; 3) investigate the hypothesis of poorly-corresponding 84 
preclinical and clinical trial designs; and 4) identify the potential gaps in clinical translation to 85 
be bridged in future approaches.  86 
Methodological approach 87 
   Studies on cell therapy for ischemic stroke published before April 3rd 2018 were identified 88 
from PubMed, Web of Science, and Scopus according to the Preferred Reporting Items for 89 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The detailed protocol is 90 
available on PROSPERO (CRD42018093214 and CRD42018096257) or in Supplemental 91 
Material. Briefly, preclinical studies describing cell transplantation in animal models of focal 92 
cerebral ischemia, and controlled clinical studies were gathered. We included the four most 93 
frequently examined outcome measures: 1) infarct size; 2) modified Neurological Severity 94 
Score (mNSS); 3) rotarod test; and 4) adhesive removal test (ART) performance. A quality 95 
score was also assigned10,11. In clinical studies, functional outcomes were measured by 96 
National Institutes of Health Stroke Scale (NIHSS), modified Barthel index (mBI), modified 97 
Rankin scale (mRS), and Fugl-Meyer scale (FMS). Standardized mean differences (SMD), 95% 98 
confidence intervals (95% CI) and statistical significances were examined using the inverse-99 
variance method12. For each outcome, the effect size was calculated using Hedges’ g and 100 
heterogeneity was calculated as I2. In view of the substantial heterogeneity in the included 101 
studies, a random effects model was applied to estimate the pooled effect size. Univariate meta-102 
regression was conducted on preclinical studies and subgroup analysis was conducted on 103 
clinical studies to explore the sources of heterogeneity. P<0.05 was considered as statistically 104 
significant and 0.05≦P<0.10 as a trend. Data were analyzed using Stata version 14.0 (Stata-105 
Corp). 106 
    A total of 3868 records from PubMed, 5041 records from Scopus, and 4073 records from 107 
Web of Science were identified. Ultimately, 355 preclinical studies with 10830 animals, and 108 
10 controlled clinical studies (phase I/II) with 460 patients were included (Fig 1). 109 
110 
Preclinical and clinical study qualities 111 
The median quality score of the preclinical studies was 5 out of 10 (interquartile range: 4-6) 112 
(Online Table 1). Randomization and blinded outcome assessment had been applied in 222 113 
(62.5%) and 203 (57.2%) of the 355 included studies, respectively. Only 23 (6.5%) studies 114 
reported allocation concealment and 10 (2.8%) studies provided a priori sample size 115 
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calculation. Animal models with comorbidities such as hypertension or diabetes were utilized 116 
in only 24 (6.8%) studies. 117 
    Nine out of the ten clinical trials had at least one source of bias according to the Cochrane 118 
Risk of Bias Tool13. Four studies were non-randomized controlled trials (NRCT), five studies 119 
did not report allocation concealment, and five studies featured a non-blinded outcome 120 
assessment. Only one trial was double-blinded. All studies reported complete outcome data, 121 
but only two provided details regarding power calculation.  122 
123 
Therapeutic effect differences in cell therapy   124 
125 
Robust efficacy of cell therapy in stroke animals 126 
Analysis of published data confirmed previous findings that cell therapy significantly 127 
improved both structural and functional outcomes in experimental stroke14-18. Although 128 
substantial inter-study heterogeneities (I2) were observed (65.7%-75.2%), the effect size was 129 
consistently large for each outcome measure (1.35 for infarct size reduction, 1.69 for mNSS, 130 
1.56 for rotarod test, and 1.56 for ART; P < 0.001, Fig 2).  131 
Funnel plotting suggested that there was a significant left-sided bias, meaning that studies 132 
with effect sizes smaller than mean values were under-reported (Fig 3). Egger’s regression test 133 
revealed a significant publication bias for each outcome (P<0.01). Nonetheless, after adjusting 134 
for publication bias by trim and fill, the mean effect sizes remained large (0.79 for infarct size, 135 
1.09 for mNSS, 1.00 for rotarod test and 1.07 for ART).  136 
137 
Potential reasons for therapeutic effect heterogeneity in preclinical studies 138 
The immunogenicity of injected cells accounted for 5.3%-16.0% of the observed 139 
heterogeneity in outcome (P<0.05). Based on the results of infarct size and ART, autologous 140 
cells had the largest effect, followed by allogeneic and xenogeneic cells; syngeneic cells did 141 
not display any significant efficacy in comparison with control treatment (Fig 4Ai, Ci, Di). 142 
    Freeze-thawing procedure accounted for up to 9.9% of the observed heterogeneity, e.g. in 143 
ART performance (P<0.01). Freshly-isolated cells were consistently associated with larger 144 
effects than frozen-thawed cells (Fig 4Aii, Bi, Dii). 145 
Cell type accounted for 7.6% of the observed heterogeneity in functional outcome (rotarod 146 
test) (P=0.0075). Treatment with NSCs showed the largest effect, followed by MSCs, MNCs, 147 
and other cells (Fig 4Ci). Cell origin, cell stemness and manipulation also contributed to the 148 
heterogeneity (Supplemental Fig 1B-E).  149 
Comorbidities also influenced outcome and explained 1.3%-5.8% of the observed 150 
heterogeneity (P<0.05). Cell treatment of comorbid animals consistently induced smaller 151 
effects than those obtained in healthy animals (Fig 4Aiii, Bii, Diii).  152 
The stroke model accounted for 2.3% of the observed heterogeneity in infarct size 153 
(P=0.0407). The intraluminal filament model was associated with the largest therapeutic effects 154 
(Fig 4Aiv). Moreover, an earlier assessment of infarct size (within one month) revealed larger 155 
effects as compared to a later assessment, suggesting that the therapeutic effect of injected cells 156 
may decline with time (Supplemental Fig 1A).  157 
The cell delivery route accounted for 8.1% of the observed heterogeneity in infarct size 158 
(P=0.0001). Intraventricular cell delivery achieved the largest effects on infarct size (Fig 4Av), 159 
but intracortical cell transplantation induced the greatest impact on mNSS performance, 160 
followed by intraventricular cell delivery (Fig 4Biii).  161 
A higher quality score tended to result in a smaller effect size (P=0.09) (Fig 4Biv). A higher 162 
impact factor of the published journal also tended to associate with a smaller effect size 163 
(P=0.0961) (Supplemental Fig 1F).    164 
165 
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Moderate cell therapy efficacy in patients166 
   Despite the small number of clinical trials, cell therapy induced a statistically significant 167 
beneficial effect in mBI (SMD=0.32, 95% CI: 0.03-0.61, P=0.032) as well as a trend in mRS 168 
(SMD=0.30, 95% CI: -0.03-0.64, P=0.078), but not in NIHSS (P=0.298) or FMS (P=0.112). 169 
The heterogeneity varied considerably with the various outcome measures (24.3%-85.0%) (Fig 170 
5).  171 
172 
Potential reasons for therapeutic effect heterogeneity in clinical trials173 
    We performed further subgroup analyses to clarify the effects of different clinical study 174 
design characteristics (Fig 6). MSCs showed a larger effect size than MNCs in mRS (0.20 vs. 175 
0.07; Fig 6Ai), mBI (0.94 vs. 0.13; Fig 6Bi), and FMS (1.77 vs. 0.35; Fig 6Di). 176 
Allogeneic/cryopreserved cells had been administered in only one study. Similar to the 177 
preclinical findings, studies using autologous/freshly-harvested cell therapy achieved better 178 
outcomes than those utilizing allogeneic/cryopreserved cells in mRS (0.37 vs. 0.17; Fig 6Aii, 179 
6Aiii), mBI (0.39 vs. 0.23; Fig 6Bii, 6Biii), and NIHSS (0.88 vs. -0.02; Fig 6Cii, 6Ciii). 180 
Furthermore, a trial using intracortical cell delivery reported better outcomes as compared to 181 
intravascular delivery in mRS (Fig 6Aiv) and NIHSS (Fig 6Civ). Randomized clinical studies 182 
revealed larger effect sizes than non-randomized ones in mRS (0.37 vs. 0.22; Fig 6Av) and 183 
NIHSS (0.78 vs. 0.08; Fig 6Cv), but smaller effect sizes in mBI (0.28 vs. 0.42; Fig 6Bv) and 184 
FMS (0.52 vs. 0.80; Fig 6Dv).  185 
186 
Preclinical and clinical study design differences: current situation and potential impact 187 
In contrast to the very positive results in animal models, therapeutic effects in clinical studies 188 
have been less impressive. It is noteworthy that current clinical studies on cell therapy for stroke 189 
are early stage clinical trials and are often underpowered to reveal all but the most prominent 190 
therapeutic effects. Nevertheless, remarkable design differences between preclinical and 191 
clinical studies were detected (Fig 7), which may affect clinical translation. Interestingly, we 192 
already identified cell immunogenicity, cryopreservation, cell type, comorbidity profiles and 193 
occlusion modality (i.e., the stroke model) as sources of effect size heterogeneity in preclinical 194 
studies. Basic preclinical study design characteristics are described in Online Table 2, and those 195 
of clinical studies are in Online Table 3.  196 
197 
Cell immunogenicity198 
The majority of the cells used in preclinical studies were allogeneic (47.9%) or xenogeneic 199 
(46.2%), but most of the clinical studies have utilized autologous cell transplants (70.9%) (Fig 200 
7A). In line with another analysis16, autologous cells have achieved better outcomes than their 201 
allogeneic counterparts in preclinical and clinical studies. Therefore, cell immunogenicity may 202 
not be a major reason for the current translational loss of efficacy. However, autologous cells 203 
were used in 25 preclinical studies, while allogeneic cells were used in only one clinical trial, 204 
and thus these results need to be interpreted with caution. Interestingly, syngeneic cells only 205 
demonstrated minor treatment effects. This contradictory result may be due to the small number 206 
of these studies and their high quality scores (median: 9 as compared to 5 for the entire data 207 
set).   208 
Autologous cell therapy avoids adverse immunological side effects after transplantation, 209 
which is clinically relevant. The effect of systemic xenogeneic cell transplantations in 210 
preclinical experiments may theoretically be related to the immunosuppressive effects of 211 
apoptotic cells diminishing secondary inflammatory brain damage. This idea was proposed 212 
more than two decades ago19, but has never been truly investigated in a stroke paradigm. If this 213 
concept is true, its clinical impact would be substantial and clearly warrants future investigation.  214 
215 
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Cryopreservation 216 
In preclinical studies, 33.1% of stroke animals received freshly harvested cells, 10.3% 217 
received cryopreserved cells, while no clear details on cryopreservation were provided in the 218 
other studies. In clinical trials, freshly harvested cells were used in 70.9% of patients with 219 
cryopreserved cells being used in the remainder (Fig 7B). The exploitation of cryopreserved 220 
cells as off-the-shelf products allows cell delivery at acute time points. However, our results 221 
indicate that frozen-thawed cells were associated with significantly reduced efficacy when 222 
compared to their freshly-harvested counterparts in preclinical and clinical trials. 223 
Cryopreserved cells may indeed exhibit lower viability, compromise immunomodulatory 224 
effects, and induce more intense or immediate blood-mediated inflammatory reactions20-23, 225 
particularly in MNC populations23. Nonetheless, some recent studies have also described 226 
comparable therapeutic effects between cryopreserved and fresh cells24-26. The exact conditions 227 
compromising the efficacy of cryopreserved cells may be complex but should be clarified as 228 
soon as possible.  229 
230 
Cell type 231 
    MSCs were the most frequently investigated cells in preclinical studies (51.5% of stroke 232 
animals), followed by NSCs (21.8%), and MNCs (14.9%) (Fig 7C). Other cells such as 233 
endothelial progenitors, induced pluripotent or embryonic stem cells, had been administered in 234 
11.9% of stroke animals. In contrast, MNCs were much more frequently given to stroke 235 
patients (55.2%). Six out of ten included clinical studies used heterogeneous MNC populations, 236 
three administered MSCs, and one utilized CD34+ cells.  237 
   The optimal cell type for ischemic stroke treatment remains unclear. Our analysis pointed to 238 
a superior effect with MSCs as compared to MNCs in both preclinical and clinical trials. The 239 
predominant use of MNCs in the clinic is likely due to practical issues such as ease of isolation 240 
and availability without time-consuming and sensitive in vitro cultivation, as well as the 241 
excellent safety profile of MNCs, compensating for their potentially lower efficacy. However, 242 
one meta-analysis of bone marrow-derived MNCs17 showed an effect size larger than that 243 
achieved with either MSCs16 or NSCs18, perhaps due to the different data searching and 244 
inclusion criteria. Analysis of preclinical studies also revealed that the trial with the overall 245 
most significant improvement involved NSCs (Fig 4Ciii), but unfortunately no clinical study 246 
on NSC transplantation could be included here due to the lack of appropriate control groups7,27. 247 
248 
Recipient comorbidities249 
More than 90% of animals were healthy before stroke induction whereas many stroke 250 
patients suffered from comorbidities such as hypertension (38.3%), diabetes (25.2%), and heart 251 
disease (30.7%). Only 5.4% of the patients were reported as being healthy before the stroke 252 
event (Fig 7D). Comorbidities themselves may exert a detrimental impact on treatment 253 
efficacy28, as confirmed also in our study. Furthermore, stroke patients often take medications 254 
such as anti-diabetics to counter comorbidities, and these compounds may interact with injected 255 
cells29,30. In addition, stroke patients are usually prescribed anti-platelet drugs for secondary 256 
stroke prevention and undergo post-stroke rehabilitation. However, few preclinical studies 257 
have investigated these potential interactions, leaving a clear knowledge gap in translational 258 
stroke research that likely affects the results obtained in subsequent clinical trials.     259 
Mimicking the complex reality of clinical patient populations in preclinical studies is 260 
expensive and time-consuming. A potential solution might be to focus on patients with a 261 
particular, more specific risk profile and to mimic that experimentally. The disadvantage of 262 
this approach will be a slower patient recruitment as only a subgroup would receive treatment, 263 
but comparability will be higher. 264 
265 
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Recipient sex and age266 
Cell therapy has been mainly provided to young (93.7%) male (85.1%) rodents (99.3%). In 267 
contrast, stroke patients were often middle-aged (40-60 years old, 54.8%) or elderly (>60 years 268 
old, 45.2%), consisting of both males and females, and were always enrolled in clinical trials 269 
without selection (Fig 7E-F). We did not find sex and age to significantly affect the efficacy of 270 
cell therapy in stroke animals. However, this kind of influence cannot be excluded simply due 271 
to the very limited number of studies assessing female and aged individuals. Indeed, gender-272 
related differences are a well-known and frequently discussed confounder for outcome in 273 
translational stroke research31. While simulating a clinically realistic sex distribution pattern in 274 
preclinical studies requires significant additional resources, neglecting sex differences 275 
introduces one more bias into experimental results 32. Moreover, there is experimental evidence 276 
that cell donor’s and recipient’s ages can influence cell treatment efficacy, particularly in 277 
commonly applied MNC populations33. 278 
279 
Cerebral vessel occlusion modalities 280 
The intraluminal filament stroke model was used in 80.5% of the studied animals. As shown 281 
above, the use of this model is associated with a larger effect size. It is also characterized by 282 
an extremely large infarct size limiting recovery processes, which is similar to the situation 283 
after large territorial infarction in humans. About 10-20% of ipsilateral corticospinal fibers do 284 
not cross in rodents, cats or monkeys, but it remains rather uncertain whether there are 285 
functionally relevant non-crossing corticospinal fibers in adult humans34. Hence, the large 286 
effect size in preclinical studies employing the filament model may be partly due to the rapid 287 
spontaneous stroke recovery mediated via activation and strengthening of the ipsilateral 288 
corticospinal pathway35, a process that can be further enhanced by cell therapy in rodents – but 289 
possibly not in humans.  290 
Moreover, 74.1% of the stroke modelling in preclinical studies was transient, which mimics 291 
the recanalization in patients achieved by thrombectomy36, thrombolysis, or that occurring 292 
spontaneously. However, only a limited number of patients experience prompt recanalization, 293 
thus the permanent occlusion models might better reflect the present-day clinical situation 294 
except for intra-arterial cell transplantation5,37,38. The current advances in recanalization 295 
approaches may lead to increasing numbers of patients receiving cell therapy immediately after 296 
recanalization in the future, warranting the use of a transient stroke model for preclinical 297 
evaluation regardless of the targeted time point of cell administration, and would allow cell 298 
transplantation in a more acute stage after stroke-onset in clinical trials.  299 
300 
Time window of cell transplantation301 
In the preclinical studies, cells were transplanted within 24h after stroke onset in 67.5%, and 302 
between 24h and 1 week in 28.2% of experiments. However, in clinical trials, cells were more 303 
often transplanted at later time points, i.e. one week or even one month after stroke-onset 304 
(67.3%). No study had transplanted cells within 24h post-stroke (Fig 7G). Cell delivery in acute 305 
phase post-stroke is considered to result primarily in neuroprotection via enhanced blood-brain 306 
barrier (BBB) integrity and modulation of post-ischemic immune responses, but it is 307 
challenging to administer cells so early in the clinic. Post-acute cell delivery potentially 308 
increases angiogenesis, neurogenesis, and axonal plasticity, offering a wider time window for 309 
cell therapies39.  310 
Although the time window was not found here to affect efficacy significantly, many 311 
preclinical studies claimed that earlier transplantation of cells could result in a better outcome40-312 
42, although no conclusive evidence has been reported16,43,44. Successful clinical stroke care 313 
involves several strictly timed therapeutic interventions, dramatically restricting the time 314 
available for complex cell treatments. For this reason in clinical trials, cells have usually been 315 
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transplanted in either the subacute or chronic post-stroke stages. A good example is the 316 
MASTERS trial that evaluated the MultiStem cell product8, which is one of the best 317 
characterized cell products in the field. The preclinical research on the MultiStem cell product 318 
revealed an excellent outcome (effect size=3.98 for infarct size and 3.00 for mNSS)45, but only 319 
modest results were observed in the clinical MASTERS trial8. It is noteworthy that the time 320 
window for patient inclusion was expanded from 36h to 48h due to logistical requirements 321 
beyond the investigators’ and sponsor’s control. Although the safety of cell transplantation was 322 
demonstrated in the final MASTERS clinical trial, no significant therapeutic effect was 323 
detected after intravenous cell infusion at 24-48h post-stroke. However, a post-hoc subgroup 324 
analysis revealed beneficial effects of cell transplantation at earlier time points (<36h), which 325 
is exactly the patient population assumed to benefit most according to the preclinical data. The 326 
currently ongoing MASTERS-2 trial will take this aspect into account. This supports our 327 
proposal that understanding the timing and mechanisms of improvement following cell therapy 328 
is essential for successful clinical translation.  329 
330 
Delivery route 331 
    Intravenous cell delivery had been performed in 51.6% of the preclinical studies, and was 332 
also predominantly chosen in clinical trials (74.9%). While intravenous cell delivery is a 333 
straightforward approach in both preclinical and clinical arenas, the optimal cell delivery route 334 
remains unclear and is likely related to the cell type used. Vu et al.16 reported better mNSS 335 
performance after intracortical MSC delivery as compared to intra-arterial and intravenous 336 
delivery, whereas Lee et al.14 found no significant effect of cell delivery route on outcome. 337 
Both preclinical and clinical data revealed better outcome of intracortical cell delivery 338 
compared to intravascular delivery. However, the utility of intracortical delivery is limited 339 
clinically due to its invasiveness46. Proof-of-concept studies may be required to assess whether 340 
the advantage of intracortical delivery outweighs the safety concerns. Indeed, the recent phase 341 
2b study (NCT02448641) of SB623 (transiently transfected MSCs overexpressing Notch-1) 342 
showed safety, but failed to show efficacy in chronic stroke patients, in contrast to the 343 
preliminary signs of efficacy from the preceding animal study47 and phase 1/2b clinical trial48. 344 
Another sham controlled trial, the recently-started PISCES 3 trial (NCT03629275) is utilizing 345 
intracranial transplantation as well, but with a different cell product, cell dose and primary 346 
outcome measures; its results are keenly anticipated. The preclinical analysis also revealed 347 
superior effects of intraventricular over intracortical cell delivery. The intraventricular route is 348 
also slightly easier to perform than intracortical administration while still bypassing the BBB, 349 
and thus may be a promising option for the future. However, the potential risk of adverse effects 350 
such as hydrocephalus must be considered. No significant difference in therapeutic effect was 351 
found between studies using intra-arterial and intravenous delivery routes, but improper intra-352 
arterial cell administration can trigger complications20, 49, 50. 353 
354 
Methodological limitations 355 
We included studies using different cell types, administration modes, etc., which increased 356 
the sample size for data analysis, particularly for clinical studies, and also enabled us to explore 357 
the sources of heterogeneity. As expected, substantial inter-study heterogeneity was observed. 358 
We addressed this in several ways: first, the heterogeneous outcome measures were 359 
standardized; second, a random-effects model was used, assuming that the treatment effect can 360 
vary across studies because of differences in study characteristics rather than by chance51; third, 361 
meta-regressions or subgroup analyses were performed to identify the sources of 362 
heterogeneity52,53. However, unexplained heterogeneity from sources that were not considered 363 
in our analysis may remain. It is noteworthy that heterogeneity cannot be avoided, and 364 
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considerable heterogeneity was also observed in previous studies using more strict inclusion 365 
criteria16-18.  366 
Moreover, the number of included clinical studies is still small. In some cases, there was 367 
only one study (e.g. allogeneic/cryopreserved) available for subgroup analysis. Thus, the 368 
validity of these results remains uncertain, and more clinical results are needed. 369 
370 
Conclusions and outlook 371 
   Although the considerable heterogeneity in preclinical data and the so-far small number of 372 
available clinical datasets make it difficult to draw any definitive conclusions, we identified 373 
substantial design differences between preclinical and clinical trials, which may contribute to 374 
the modest efficacy of cell therapy in stroke patients and have important implications for future 375 
translational projects.  376 
    We propose several suggestions for preclinical studies which may prevent translational 377 
failure. First, in confirmatory preclinical studies, there should be greater similarity to patient 378 
populations likely to be treated in clinical trials. For example, use of aged male and female 379 
animals with comorbidities such as hypertension and diabetes would better reflect the clinical 380 
reality. Second, drug-cell interactions require further investigation. Third, permanent, instead 381 
of transient, stroke models might represent a more clinically relevant strategy when evaluating 382 
the efficacy of cell therapies54,55, particularly when targeting patient populations that cannot 383 
benefit from recanalization. Fourth, wider therapeutic time windows would benefit more 384 
patients. Hence, it would be beneficial to conduct more experimental studies testing cell 385 
transplantation in the subacute and chronic stroke stages. Fifth, it would be advantageous to 386 
devise a battery of sensory-motor function tests sensitive at detecting long-term impairment 387 
and conducive to repeated testing without developing compensatory strategies56. Last but not 388 
least, the therapeutic mechanisms of cell therapy still need to be clarified. 389 
   Several recommendations for clinical studies also emerge from our meta-analysis. First, 390 
freshly-harvested, autologous cells are recommended for future clinical trials to ensure 391 
maximal effects, if logistical challenges can be overcome. Second, studies of cell 392 
transplantation with more acute time windows (within 24h or 1 week) after stroke should be 393 
conducted, as these better resemble the situation in successful preclinical studies. Third, due to 394 
the extensive heterogeneity of the stroke patients, it will be crucial to identify the optimal 395 
recipients that are most likely to benefit from cell treatments, and to devise biomarkers that 396 
pinpoint such patients57. Last, multi-centered, randomized, double blinded clinical trials with 397 
larger sample sizes are urgently needed to evaluate the effect of cell therapy in stroke patients. 398 
   Finally, an illustration of comparability between preclinical and clinical studies by a 399 
similarity check list might help when translating a specific cell product from bench to clinic: 400 
1) same time window (acute, subacute or chronic); 2) same delivery route; 3) same cell dose 401 
(number of cells per kg/body surface area); 4) same cell immunogenicity; 5) same preparation 402 
procedure before transplantation (e.g. fresh vs. cryopreservation); 6) same target infarcts (e.g., 403 
hemispherical infarcts of middle cerebral artery territory only, with or without reperfusion); 7) 404 
matched sex profile; 8) matched age; 9) same comorbidity; 10) same concomitant treatment.  405 
406 
Acknowledgements 407 
We thank the University of Eastern Finland Library for kind help while determining the optimal 408 
search strategy, Elina Hämäläinen for her assistance in reviewing the literature, and Mikko 409 
Myllyniemi for his contribution to data extraction. This work was supported by the 410 
RESSTORE project (grant 681044) (www.resstore.eu). Li-li Cui was supported by a fellowship 411 
from the Faculty of Health Sciences, University of Eastern Finland and Finnish Cultural 412 
Foundation-Central Fund. Anna-Maija Tolppanen acknowledges the funding from the 413 
Academy of Finland (grants 295334 and 307232). 414 
11 
415 
Author Contributions 416 
LC, AT, JB and JJ contributed to the conception and design of the study; LC, DG, AT, JB and 417 
JJ contributed to the acquisition and analysis of data; LC, DG, AT, JB and JJ contributed to 418 
drafting the text and preparing the figures. 419 
420 
Potential Conflict of Interest 421 
None. 422 
423 
12 
References 424 
1. Li Y, Chopp M, Chen J, et al. Intrastriatal transplantation of bone marrow nonhematopoietic 425 
cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab 426 
2000; 20:1311-1319. 427 
2. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 428 
2006; 7:395-406. 429 
3. Eckert MA, Vu Q, Xie K, et al. Evidence for high translational potential of mesenchymal 430 
stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab 431 
2013; 33:1322-1334.  432 
4. Wang J, Yu L, Jiang C, et al. Bone marrow mononuclear cells exert long-term 433 
neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and 434 
angiogenesis. Brain Behav Immun 2013; 34:56-66.  435 
5. Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-arterial bone marrow mononuclear 436 
cells in ischemic stroke: a pilot clinical trial. Stroke 2012; 43:2242-2244. 437 
6. Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous 438 
mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 439 
28:1099-1106.  440 
7. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic 441 
ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 2016; 388:787-796.  442 
8. Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor 443 
cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-444 
controlled, phase 2 trial. Lancet Neurol 2017; 16:360-368. 445 
9. Ramirez FD, Motazedian P, Jung RG, et al. Methodological rigor in preclinical 446 
cardiovascular studies: targets to enhance reproducibility and promote research translation. 447 
Circ Res 2017; 120:1916-1926.448 
10. Macleod MR, Fisher M, O'Collins V, et al. Good laboratory practice: preventing introduction 449 
of bias at the bench. Stroke 2009; 40: e50–e52.450 
11. Macleod MR, O’Collins T, Howells DW, et al. Pooling of animal experimental data reveals 451 
influence of study design and publication bias. Stroke 2004; 35: 1203–1208. 452 
12. Vesterinen HM, Sena ES, Egan KJ, et al. Meta-analysis of data from animal studies: a 453 
practical guide. J Neurosci Methods 2014; 221:92-102. 454 
13. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing 455 
risk of bias in randomized trials. BMJ 2011; 343: d5928. 456 
14. Lees JS, Sena ES, Egan KJ, et al. Stem cell-based therapy for experimental stroke: 457 
a systematic review and meta-analysis. Int J Stroke 2012; 7: 582-528. 458 
15. Janowski M, Walczak P, Date I. 459 
Intravenous route of cell delivery for treatment of neurological disorders: a meta-460 
analysis of preclinical results. Stem Cells Dev 2010; 19: 5-16.  461 
16. Vu Q, Xie K, Eckert M, et al. Meta-analysis of preclinical studies of mesenchymal stromal 462 
cells for ischemic stroke. Neurology 2014; 82:1277-1286. 463 
17. Vahidy FS, Rahbar MH, Zhu H, et al. Systematic review and meta-analysis of bone marrow-464 
derived mononuclear cells in animal models of ischemic stroke. Stroke 2016; 47:1632-1639.465 
13 
18. Chen L, Zhang G, Gu Y, et al. Meta-466 
analysis and systematic review of neural stem cells therapy for experimental ischemia stroke 467 
in preclinical studies. Sci Rep 2016; 6: 32291. 468 
19. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 469 
1997; 390:350-351.470 
20. Cui LL, Kinnunen T, Boltze J, et al. Clumping and viability of bone marrow derived 471 
mesenchymal stromal cells under different preparation procedures: A flow cytometry-based 472 
in vitro study. Stem Cells Int 2016; 2016:1764938. 473 
21. Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display 474 
impaired immunomodulatory and therapeutic properties? Stem Cells 2014; 32:2430-2442.  475 
22. François M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display 476 
impaired immunosuppressive properties as a result of heat-shock response and impaired 477 
interferon-γ licensing. Cytotherapy 2012; 14:147-152. 478 
23. Weise G, Lorenz M, Pösel C, et al. Transplantation of cryopreserved human umbilical cord 479 
blood mononuclear cells does not induce sustained recovery after experimental stroke in 480 
spontaneously hypertensive rats. J Cereb Blood Flow Metab 2014; 34: e1-9.  481 
24. Cruz FF, Borg ZD, Goodwin M, et al. Freshly thawed and continuously cultured human bone 482 
marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways 483 
inflammation in immunocompetent mice. Stem Cells Transl Med 2015; 4:615-624. 484 
25. Luetzkendorf J, Nerger K, Hering J, et al. Cryopreservation does not alter main 485 
characteristics of Good Manufacturing Process-grade human multipotent mesenchymal 486 
stromal cells including immunomodulating potential and lack of malignant transformation. 487 
Cytotherapy 2015; 17:186-198. 488 
26. Yang B, Parsha K,Schaar K, et al Cryopreservation of bone marrow mononuclear cells alters 489 
their viability and subpopulation composition but not their treatment effects in a rodent 490 
stroke model. Stem Cells Int 2016; 2016: 5876863.491 
27. Lu WS, Li ZC, Tian ZM, et al. Clinical transplantation of human embryonic neural stem 492 
cells for the treatment of cerebral infarction sequelae. Neurosurg 2013; 23:58-60.493 
28. Chen J, Ye X, Yan T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in 494 
diabetic rats. Stroke 2011; 42:3551-3558. 495 
29. Ortega FJ, Jolkkonen J, Mahy N, et al. Glibenclamide enhances neurogenesis and improves 496 
long-term functional recovery after transient focal cerebral ischemia. J Cereb Blood Flow 497 
Metab 2013; 33: 356–364. 498 
30. Pirzad Jahromi G, Seidi S, Sadr SS, et al. Therapeutic effects of a combinatorial treatment of 499 
simvastatin and bone marrow stromal cells on experimental embolic stroke. Basic Clin 500 
Pharmacol Toxicol 2012; 110: 487-493. 501 
31. Ahnstedt H, McCullough LD, Cipolla MJ. The importance of considering sex differences in 502 
translational stroke research. Transl Stroke Res. 2016;7:261-273.503 
32. Sohrabji F, Park MJ, Mahnke AH. Sex differences in stroke therapies. J Neurosci Res 2017; 504 
95:681-691.505 
33. Wagner DC, Bojko M, Peters M, et al. Impact of age on the efficacy of bone marrow 506 
mononuclear cell transplantation in experimental stroke. Exp Transl Stroke Med 2012; 4:17.507 
14 
34. Alawieh A, Tomlinson S, Adkins D, et al. Preclinical and clinical evidence on ipsilateral 508 
corticospinal projections: implication for motor recovery. Transl Stroke Res 2017; 8: 529-509 
540. 510 
35. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behavior. Nat Rev 511 
Neurosci 2009; 10: 861-872. 512 
36. Sutherland BA, Neuhaus AA, Couch Y, et al. The transient intraluminal filament middle 513 
cerebral artery occlusion model as a model of endovascular thrombectomy in stroke. J Cereb 514 
Blood Flow Metab. 2016; 36:363-369. 515 
37. Ghali AA, Yousef MK, Ragab OA, et al. Intra-arterial infusion of autologous bone marrow 516 
mononuclear stem cells in subacute ischemic stroke patients. Front Neurol 2016;7:228.517 
38. Bhatia V, Gupta V, Khurana D, et al. Randomized assessment of the safety and efficacy of 518 
intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR Am J 519 
Neuroradiol 2018;39:899-904. 520 
39. George PM, Steinberg GK. Novel stroke therapeutics: Unraveling stroke pathophysiology 521 
and its impact on clinical treatments. Neuron 2015; 87:297-309. 522 
40. Wang LQ, Lin ZZ, Zhang HX, et al. Timing and dose regimens of marrow mesenchymal 523 
stem cell transplantation affect the outcomes and neuroinflammatory response after ischemic 524 
stroke. CNS Neurosci Ther 2014; 20: 317-326.  525 
41. Boltze J, Schmidt UR, Reich DM, et al. Determination of the therapeutic time window for 526 
human umbilical cord blood mononuclear cell transplantation following 527 
experimental stroke in rats. Cell Transplant 2012; 21:1199-1211. 528 
42. Toyoshima A, Yasuhara T, Kameda M, et al. Intra-arterial transplantation of allogeneic 529 
mesenchymal stem cells mounts neuroprotective effects in a transient ischemic stroke model 530 
in rats: Analyses of therapeutic time window and its mechanisms. PLoS One 2015; 10: 531 
e0127302.  532 
43. Doeppner TR, Kaltwasser B, Teli MK, et al. Effects of acute versus post-acute systemic 533 
delivery of neural progenitor cells on neurological recovery and brain remodeling after focal 534 
cerebral ischemia in mice. Cell Death Dis 2014; 5: e1386. 535 
44. Mitkari B, Nitzsche F, Kerkelä E, et al. Human bone marrow mesenchymal stem/stromal 536 
cells produce efficient localization in the brain and enhanced angiogenesis after intra-arterial 537 
delivery in rats with cerebral ischemia, but this is not translated to behavioral recovery. 538 
Behav Brain Res 2014; 259:50-59. 539 
45. Yang B, Hamilton JA, Valenzuela KS, et al. Multipotent adult progenitor cells enhance 540 
recovery after stroke by modulating the immune response from the spleen. Stem Cells 2017; 541 
35: 1290-1302. 542 
46. Boltze J, Arnold A, Walczak P, et al. The Dark Side of the Force - Constraints and 543 
Complications of Cell Therapies for Stroke. Front Neurol 2015; 6:155. 544 
47. Yasuhara T, Matsukawa N, Hara K, et al. Notch-induced rat and human bone marrow stromal 545 
cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke 546 
animals. Stem Cells Dev. 2009;18:1501-14. 547 
48. Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in 548 
chronic ischemic stroke patients after implantation of modified bone marrow-derived 549 
mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018:1-11. 550 
15 
49. Cui LL, Kerkelä E, Bakreen A, et al. The cerebral embolism evoked by intra-arterial delivery 551 
of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion 552 
velocity. Stem Cell Res Ther 2015;6:11.553 
50. Cui LL, Nitzsche F, Pryazhnikov E, et al. Integrin α4 overexpression on rat mesenchymal 554 
stem cells enhances transmighration and reduces cerebral embolism after intracarotid 555 
injection. Stroke 2017;48:2895-2900. 556 
51. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 557 
2011;342:d549.558 
52. Antonic A, Sena ES, Lees JS, et al. Stem cell transplantation in traumatic spinal cord injury: 559 
A systematic review and meta-analysis of animal studies. PLoS Biol. 2013;11:e1001738. 560 
53. Kanelidis AJ, Premer C, Lopez J, et al. Route of delivery modulates the efficacy of 561 
mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical 562 
studies and clinical trials. Circ Res. 2017; 120:1139-1150. 563 
54. Corbett D, Carmichael ST, Murphy TH, et al. Enhancing the alignment of the preclinical and 564 
clinical stroke recovery research pipeline: Consensus-based core recommendations from the 565 
Stroke Recovery and Rehabilitation Roundtable translational working group. Int J Stroke 566 
2017; 12: 462-471.567 
55. Modo MM, Jolkkonen J, Zille M, et al. Future of animal modeling for poststroke tissue 568 
repair. Stroke 2018; 49:1099-1106.569 
56. Cui LL, Golubczyk D, Jolkkonen J. Top 3 behavioral tests in cell therapy studies after stroke: 570 
difficult to stop a moving train. Stroke 2017; 48:3165-3167. 571 
57. Boyd LA, Hayward KS, Ward NS, et al. Biomarkers of stroke recovery: Consensus-based 572 
core recommendations from the Stroke Recovery and Rehabilitation Roundtable. 573 
Neurorehabil Neural Repair 2017; 31: 864-876. 574 
575 
16 
Figure Legends 576 
577 
Figure 1. PRISMA flowchart.  578 
Figure 2. Effect sizes of (A) infarct size reduction, (B) mNSS, (C) rotarod test performance, 579 
and (D) ART performance in preclinical studies.  580 
Figure 3. Funnel plot of (A) infarct size reduction, (B) mNSS, (C) rotarod test performance, 581 
and (D) ART performance in preclinical studies. 582 
Figure 4. Study characteristics that significantly accounted for effect size heterogeneity in 583 
different outcome measures. (A) infarct size reduction: (i) cell immunogenicity; (ii) cell 584 
cryopreservation; (iii) use of animals with comorbidity; (iv) stroke model; (v) delivery time 585 
relative to stroke-onset. (B) mNSS: (i) cell cryopreservation; (ii) use of animals with 586 
comorbidity; (iii) delivery route; (iv) quality score of studies. (C) rotarod test: (i) cell 587 
immunogenicity; (ii) cell type. (D) ART: (i) cell immunogenicity; (ii) cell cryopreservation; 588 
(iii) use of animals with comorbidity. The dotted line indicates the pooled effect size of all 589 
studies. 590 
Figure 5. Effect sizes of different outcome measures (mRS, mBI, NIHSS, and FMS) in 591 
clinical studies. Y: yes, N: no, Auto: autologous, Allo: allogeneic, Cryo: cryopreservation, N 592 
(T/C): number of patients (treated/control) 593 
Figure 6. Subgroup analysis of mRS (A), mBI (B), NIHSS (C) and FMS (D) in clinical 594 
studies. (A-D): (i) cell type; (ii) cell immunogenicity; (iii) cell cryopreservation; (iv) delivery 595 
route; (v) randomization. The dotted line indicates the pooled effect size of all studies. 596 
Figure 7. Study design discrepancies between preclinical and clinical studies: (A) 597 
immunogenicity of transplanted cells; (B) cell cryopreservation; (C) cell type; (D) 598 
comorbidities of stroke individuals; (E) age of stroke individuals; (F) sex profile; (G) time of 599 
cell transplantation.600 
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